{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:27:06Z","timestamp":1785583626249,"version":"3.56.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>We present the case of a 61-year-old patient infected with chronic hepatitis C virus (HCV) genotype 3, F1 fibrosis and history of short bowel syndrome, dependent on total parenteral nutrition (TPN) who was referred to the clinical pharmacist for HCV treatment. Following 12 weeks of treatment with crushed, orally administered sofosbuvir\/velpatasvir (SOF\/VEL) the patient was unable to achieve sustained virologic response (SVR12), suggesting that this therapy may be ineffective in patients with short bowel syndrome.<\/jats:p>","DOI":"10.1177\/08971900251352671","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:35:26Z","timestamp":1750131326000},"page":"231-234","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic Hepatitis C Treatment Failure With Crushed Sofosbuvir\/Velpatasvir in a Patient With Total Parenteral Nutrition-dependent Short Bowel Syndrome"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-0054","authenticated-orcid":false,"given":"Noelle E.","family":"Nelson","sequence":"first","affiliation":[{"name":"University of California, Davis Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"Centers for Disease Control and Prevention. Hepatitis C surveillance. 2022. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2022surveillance\/hepatitis-c.htm. (Accessed August 21 2024)."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy585"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"e_1_3_5_5_2","article-title":"August 1, 2024 update","author":"Medi-Cal Rx Contract Drug List","unstructured":"Medi-Cal Rx Contract Drug List. August 1, 2024 update. California Department of Healthcare Services. https:\/\/medi-calrx.dhcs.ca.gov\/cms\/medicalrx\/static-assets\/documents\/provider\/forms-and-information\/cdl\/Medi-Cal_Rx_Contract_Drugs_List_FINAL.pdf. (Accessed August 21, 2024).","journal-title":"California Department of Healthcare Services"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.018"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000518306"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz326"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105934"},{"key":"e_1_3_5_10_2","unstructured":"Joshi S Cohen M Katz R et al. A case series of safety and efficacy of crushed sofosbuvir\/velpatasvir in hepatitis C infected patients. American Association for the Study of Liver Diseases (AASLD): The Liver Meeting Digital Experience. November 12-15 2021. https:\/\/www.natap.org\/2021\/AASLD\/AASLD_12.htm"},{"key":"e_1_3_5_11_2","unstructured":"Epclusa (sofosbuvir\/velpatasvir) [prescribing information]. Foster City CA: Gilead Sciences Inc; 2022."},{"key":"e_1_3_5_12_2","unstructured":"University of Liverpool. HEP drug interactions. https:\/\/www.hep-druginteractions.org\/. (Accessed August 21 2024)."},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.033"},{"key":"e_1_3_5_14_2","unstructured":"Epclusa\u00ae (sofosbuvir\/velpatasvir) Crushing or Splitting Tablets. Foster City CA: Gilead Sciences Inc. https:\/\/www.askgileadmedical.com\/docs\/epclusa\/epclusa-crushing-or-splitting-of-tablets-and-pellets\/pdf. (Accessed August 21 2024)."},{"key":"e_1_3_5_15_2","volume-title":"Epclusa\u00ae (Sofosbuvir\/velpatasvir) Stomach\/Intestinal Absorption Conditions","unstructured":"Epclusa\u00ae (Sofosbuvir\/velpatasvir) Stomach\/Intestinal Absorption Conditions. Foster City, CA: Gilead Sciences, Inc. https:\/\/www.askgileadmedical.com\/docs\/epclusa\/epclusa-stomach-intestinal-absorption-conditions\/pdf. (Accessed January 30, 2025)."},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn421"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.032"},{"key":"e_1_3_5_18_2","unstructured":"Laboratories ARUP. Fentanyl and metabolite serum or plasma quantitative. Accessible from. https:\/\/ltd.aruplab.com\/Tests\/Pub\/2011776?_gl=1*rig7vu*_ga*MTUyMDU0MzU0NS4xNzQzNTMwMTM4*_ga_Z8H49DQE4D*MTc0MzUzMDEzNy4xLjEuMTc0MzUzMDE5MS4wLjAuMA. (Accessed April 1 2025)."}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251352671","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251352671","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251352671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:54Z","timestamp":1777509234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251352671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/08971900251352671"],"URL":"https:\/\/doi.org\/10.1177\/08971900251352671","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}